BRIEF-Syros Announces Clinical Updates And 2022 Goals To Support Its Advancement To A Fully Integrated Biopharmaceutical Company

BY Reuters
— 7:23 AM ET 01/10/2022

Jan 10 (Reuters) - Syros Pharmaceuticals Inc (SYRS):

* SYROS ANNOUNCES CLINICAL UPDATES AND 2022 GOALS TO SUPPORT ITS ADVANCEMENT TO A FULLY INTEGRATED BIOPHARMACEUTICAL COMPANY

* SYROS PHARMACEUTICALS INC (SYRS) - EXPECTS TO REPORT DATA FROM THREE CLINICAL TRIALS ACROSS HEMATOLOGY AND SELECTIVE CDK INHIBITOR PROGRAMS IN 2022

* SYROS PHARMACEUTICALS INC (SYRS) - NOW EXPECTS TO INITIATE PHASE 1 SINGLE AGENT TRIAL OF SY-5609 IN HEMATOLOGIC MALIGNANCIES IN 2H 2022

* SYROS PHARMACEUTICALS INC (SYRS) - EXPECTS TO NOMINATE DEVELOPMENT CANDIDATE FROM CDK12 PROGRAM IN 2H 2022 Source text for Eikon: Further company coverage:

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Stock Details

Enter Company or Symbol. Press down arrow for suggestions, or Escape to return to entry field.

RELATED RESOURCES

BRIEF-Syros Announces Clinical Updates And 2022 Goals To Support Its Advancement To A Fully Integrated Biopharmaceutical Company

More SYRS News